57509-50-9

Usage

InChI:InChI=1/C16H12Cl2O2/c1-16(10-5-3-2-4-6-10)8-9-7-11(19)13(17)14(18)12(9)15(16)20/h2-7,19H,8H2,1H3

Upstream product

• 57713-17-4 2-methyl-2-phenyl-5-methoxy-6,7-dichloro-1-indanone 
• 83-33-0 inden-1-one 
• 88494-66-0 (S)-(+)-6,7-dichloro-5-methoxy-2-methyl-2-phenyl-1-indanone 
• 53107-36-1 1-(2,3-dichloro-4-methoxyphenyl)-2-bromo-2-methyl-1-propanone 
• 53107-37-2 1-(2,3-dichloro-4-methoxyphenyl)-2-methylene-1-propanone 
• 53107-35-0 2',3',-Dichloro-4'-methoxyisobutyrophenone 
• 1984-59-4 2,3-dichloroanisole 

Downstream Products

• 81166-30-5 4-(6,7-Dichloro-2-methyl-1-oxo-2-phenyl-indan-5-yloxy)-butyric acid ethyl ester 
• 61000-46-2 5-(allyloxy)-6,7-dichloro-2-methyl-2-phenyl-1-indanone 
• 850331-44-1 4-(6,7-dichloro-2-methyl-1-oxo-2-phenyl-indan-5-yloxymethyl)-benzonitrile 
• 71500-91-9 6,7-dichloro-2-methyl-2-phenyl-5-trifluoromethylsulfonyloxy-1-indanone 
• 71500-88-4 (6,7-dichloro-1-oxo-2-methyl-2-phenyl-5-indanyl)acetic acid 
• 66015-60-9 (1-oxo-2-methyl-2-phenyl-6,7-dichloro-5-indanyloxy)acetonitrile 
• 67976-26-5 6,7-dichloro-2-methyl-2-phenyl-5-(1H-tetrazol-5-ylmethoxy)-indan-1-one 
• 56049-88-8 (+/-)-Indacrinone 
• 66015-31-4 [1-Oxo-2-(4-aminomethylphenyl)-2-methyl-6,7-dichloro-5-indanyloxy]acetic acid 
• 66015-32-5 [1-oxo-2-methyl-2-(4-sulfamoylphenyl)-6,7-dichloro-5-indanyloxy]acetic acid 
• 66015-59-6 [1-Oxo-2-(4-chlorosulfonylphenyl)-2-methyl-6,7-dichloro-5-indanyloxy]acetic acid 
• 57297-16-2 S-(+)-indacrinone 
• 88494-66-0 (S)-(+)-6,7-dichloro-5-methoxy-2-methyl-2-phenyl-1-indanone 
• 88440-75-9 ((S)-6,7-Dichloro-2-methyl-1-oxo-2-phenyl-indan-5-yloxy)-acetic acid ethyl ester 

Relevant academic research and scientific papers

Process for preparing a manipulated enantiomer mixture by asymmetric chiral phase transfer catalysis

A process is disclosed for obtaining manipulated proportions of the (+) and (-) enantiomers of [(6,7-dichloro-2,3-dihydro-2-methyl-1-oxo-2-phenyl-1H-inden-5-yl)oxy]acetic acid by asymmetric chiral phase transfer catalysis.

(1-Oxo-2-aryl or thienyl-2-substituted-5-indanyloxy (or thio) alkanoic acids, and derivatives thereof

[1-Oxo-2-aryl or thienyl-2-substituted-5-indanyloxy (or thio)]aklanoic acid, derivatives thereof, their salts, esters and amides are disclosed. The products display a dual pharmaceutical utility in that they exhibit diuretic, saluretic and uricosuric activity. Also disclosed are processes for the preparation of such [1-oxo-2-aryl or thienyl-2-substituted-5-indanyloxy (or thio)]alkanoic acids, pharmaceutical compositions comprising therapeutically effective amounts of such compounds and methods of treatment comprising administering such compounds and compositions.

[1-Hydroxy-5-indanyloxy (or thio)]-alkanoic acids

[1-Hydroxy-5-indanyloxy (or thio)]alkanoic acids and their salts, esters and amides are disclosed. The products display a dual pharmaceutical utility in that they exhibit diuretic, saluretic and hypouricemic activity. The acid products are prepared by several synthetic methods.

[1-Hydroximino-2,2-disubstituted-5-indanyloxy-(or thio)]alkanoic acids

[1-Hydroximino-2,2-disubstituted-5-indanyloxy-(or thio)]alkanoic acids and their salt, ester, anhydride, amide and 5-tetrazolyl derivatives are disclosed. The products display a dual pharmaceutical utility in that they exhibit diuretic, saluretic and uricosuric activity. The acid products are prepared by treating a 1-oxo-2,2-disubstituted-5-indanyloxy(or thio)alkanoic acids or derivatives thereof with hydroxylamine in the presence of a base.

6-Oxo-7-substituted and 7,7-disubstituted-6H-indeno-[5,4-b]furan (and thiophene) carboxylic acids

6-Oxo-7,7-disubstituted-1,2,7,8-tetrahydro (and 7,8-dihydro)-6H-indeno-[5,4-b]furan (and thiophene)carboxylic acids, the salt, ester and amide derivatives thereof and combinations of these compounds with antikaluretic agents are disclosed having diuretic-saluretic, uricosuric and antihypertensive activity.